An interventional study of Autologous Platelet-Rich Plasma (PRP) and Gonadotropin in Polycystic Ovary Syndrome (PCOS), sponsored by Bangladesh Medical University. Completed at 1 site in Bangladesh. Open to female participants aged 18 Years to 35 Years. Per ClinicalTrials.gov, last updated 2026-08-20.
Sponsored by Bangladesh Medical University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Polycystic Ovary Syndrome with a site in Bangladesh — 2 open to participants now, 4 under way, none of them phase 3. Polycystic Ovary Syndrome · Bangladesh.
Among the 12 studies in Polycystic Ovary Syndrome with a site in Bangladesh, this one is the 11th largest by enrollment, is one of 5 that started in 2025, is one of 7 with no phase, and was the 11th registered.
958 studies on the registry are indexed under Polycystic Ovary Syndrome; 175 are open to participants now.
Browse Polycystic Ovary Syndrome studies →2 of the 12 studies in Polycystic Ovary Syndrome with a site in Bangladesh are open now. Recruiting first, the newest first:
Mst.Sumyara Khatun · Sites in Bangladesh
Ages 18–40 · Women only
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh · Sites in Bangladesh
Ages 18–36 · Women only
A study can be open while its sites in Bangladesh have not opened yet or have stopped. Only those recruiting at a site in Bangladesh →
Of the 119 Polycystic Ovary Syndrome studies recruiting now, 11 (9%) set no upper age limit and 105 (88%) stop at 75 or younger; 23 take children under 18; 41 take healthy volunteers.
This study: 18 Years to 35 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 2 · Phase 3 3 · Phase 4 1
First in 2023; this study’s year is marked. 5 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 50 is below the median of 70 across 699 interventional studies indexed under Polycystic Ovary Syndrome.
Median enrollment 67 across the 12 interventional studies. Of the 8 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 12 has an industry lead sponsor. The 4 most frequent:
Bangladesh Medical University is the lead sponsor of 45 studies on the registry; 27 are open to participants now.
Bangladesh Medical University has 1 study filed under Polycystic Ovary Syndrome — fewer than ten, so there is no comparison to draw.
1 of the studies in Polycystic Ovary Syndrome with a site in Bangladesh that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05680805Bangabandhu Sheikh Mujib Medical University, Dhaka, BangladeshMetabolic Responses of Metformin and Genetic Polymorphisms of SLC22A1 Gene in PCOS | 2026-12-30 |
Add it to your calendar (.ics) → With an account.
Among the 12 studies in Polycystic Ovary Syndrome with a site in Bangladesh, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this randomized clinical trial is to compare autologous platelet-rich plasma (PRP) with gonadotropin for improving ovarian response in women with letrozole-resistant polycystic ovary syndrome (PCOS). Researchers will compare the two treatments to assess ovarian response, ovulation rates, and pregnancy rates. Participants will be randomly assigned to receive either intra-ovarian autologous PRP or gonadotropin treatment and will be followed for three consecutive cycles.
Polycystic ovary syndrome (PCOS) is a common reproductive endocrine disorder that may cause anovulation and infertility. Letrozole is a first-line ovulation induction agent; however, a proportion of women with PCOS are resistant to standard-dose letrozole and may require second-line treatment such as gonadotropin therapy. Gonadotropin treatment can be effective but requires monitoring because of the risks of ovarian hyperstimulation and multiple pregnancy. This randomized clinical trial is designed to evaluate and compare the effects of intra-ovarian autologous platelet-rich plasma (PRP) and gonadotropin treatment on ovarian response in women with letrozole-resistant PCOS.
Eligible women attending the Department of Reproductive Endocrinology and Infertility, Bangladesh Medical University, will be identified according to the Rotterdam diagnostic criteria for PCOS and screened according to the study inclusion and exclusion criteria. Participants will receive detailed information about the study and provide written informed consent before enrollment. Sociodemographic information, relevant clinical history, and investigations will be recorded using a structured data collection sheet.
Participants will be randomly allocated into two intervention groups using a computer-generated random number sequence. Participants in the experimental group will receive 5 mL of autologous platelet-rich plasma in each ovary by laparoscopy during the proliferative phase of the menstrual cycle. Following the procedure, participants will be monitored for spontaneous ovulation for three consecutive months.
Participants in the gonadotropin group will receive gonadotropin stimulation for three consecutive cycles. Follicular development will be monitored by transvaginal ultrasonography. Gonadotropin stimulation will be administered according to the study protocol, followed by human chorionic gonadotropin triggering when a mature follicle is identified. Timed intercourse will be advised following triggering. Ovulation will subsequently be assessed by mid-luteal serum progesterone measurement.
Tubal patency will be assessed as part of the infertility evaluation to exclude tubal factor infertility. In participants allocated to the PRP group, tubal evaluation will be performed during the laparoscopic procedure undertaken for intra-ovarian PRP administration. In participants allocated to the gonadotropin group, tubal evaluation will be performed before initiation of gonadotropin stimulation. Participants found to have bilateral tubal block will be excluded from the study.
The primary outcome is ovarian response, assessed by transvaginal ultrasonography, including the proportion of participants developing follicles measuring at least 14 mm, the proportion developing mature follicles measuring 18-25 mm, and endometrial thickness of at least 7 mm. Ovulation rate will be assessed by mid-luteal serum progesterone, with a progesterone concentration greater than 3 ng/mL considered indicative of ovulation. Pregnancy rate will be assessed by serum beta-human chorionic gonadotropin.
Participants will also be monitored for treatment-related adverse effects, including ovarian hyperstimulation syndrome, multiple pregnancy, and injection-site reactions. The study will compare ovarian response, ovulation rate, and pregnancy rate between the intra-ovarian autologous PRP group and the gonadotropin group over three consecutive treatment cycles/months.
The study aims to determine whether intra-ovarian autologous PRP may improve ovarian response and ovulation in women with letrozole-resistant PCOS compared with gonadotropin treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive intra-ovarian autologous platelet-rich plasma (PRP) by laparoscopy and will be followed for ovarian response, ovulation, and pregnancy outcomes for three consecutive cycles
Biological: Autologous Platelet-Rich Plasma (PRP)
Participants will receive gonadotropin treatment for three consecutive cycles and will be followed for ovarian response, ovulation, and pregnancy outcomes.
Drug: Gonadotropin
Participants will receive 5 mL of autologous platelet-rich plasma (PRP) in each ovary by laparoscopy during the proliferative phase of the menstrual cycle. Following the procedure, participants will be monitored for spontaneous ovulation for three consecutive cycles.
Participants will receive recombinant follicle-stimulating hormone (rFSH) 75 IU intramuscularly on days 5 and 7 of the menstrual cycle, followed by human menopausal gonadotropin (hMG) 75 IU intramuscularly on days 9 and 11. Follicular development will be monitored by transvaginal ultrasonography. When at least one mature follicle measuring 18-25 mm is identified, ovulation will be triggered with human chorionic gonadotropin (hCG) 5,000 IU intramuscularly, followed by timed intercourse.
Proportion of Participants With Developing Follicles ≥14 mm
Developing follicles will be assessed by transvaginal ultrasonography. A follicle measuring ≥14 mm in diameter will be considered a developing follicle.
Time frame: Day 12 to Day 14 of each treatment cycle, where each treatment cycle is defined as one menstrual cycle from the first day of menstrual bleeding to the first day of the next menstrual bleeding, for up to three consecutive treatment cycles.
Proportion of Participants With Mature Follicles
Mature follicle will be defined as a follicle measuring 18 to 25 mm in diameter on transvaginal ultrasonography.
Time frame: Day 12 to Day 14 of each treatment cycle, where each treatment cycle is defined as one menstrual cycle from the first day of menstrual bleeding to the first day of the next menstrual bleeding, for up to three consecutive treatment cycles.
Proportion of Participants With Endometrial Thickness ≥7 mm
Endometrial thickness will be measured by transvaginal ultrasonography. An endometrial thickness of ≥7 mm will be considered the target response
Time frame: Day 12 to Day 14 of each treatment cycle, where each treatment cycle is defined as one menstrual cycle from the first day of menstrual bleeding to the first day of the next menstrual bleeding, for up to three consecutive treatment cycles.
Proportion of Participants With Ovulation
Ovulation will be assessed by mid-luteal serum progesterone measurement. A serum progesterone level \>3 ng/mL will be considered indicative of ovulation
Time frame: 7 days after ovulation trigger in each treatment cycle, where each treatment cycle is defined as one menstrual cycle from the first day of menstrual bleeding to the first day of the next menstrual bleeding, for up to three consecutive treatment cycles.
Pregnancy Rate
Pregnancy will be assessed by quantitative serum beta-human chorionic gonadotropin (β-hCG) measurement one week after a missed menstrual period. Clinical pregnancy will be confirmed by transvaginal ultrasonography at 6-8 weeks of gestation
Time frame: One week after a missed menstrual period in each treatment cycle, where each treatment cycle is defined as one menstrual cycle from the first day of menstrual bleeding to the first day of the next menstrual bleeding, for up to three consecutive treatment
Plan to share: No
No publications or documents are linked to this record.
Ran from Jun 2025 to primary completion in May 2026, 11 months.
Of 204 non-industry interventional studies with no phase under Polycystic Ovary Syndrome, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 37. This study's 11 months is below that.
Counting every sponsor, half of 219 studies reached it within 18 months; a quarter within 7 and three quarters within 37.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Platelet rich plasma
Bangladesh Medical University